Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992025 | 0.87 | NPC1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4997507 | 0.85 | MAPK1 (0.42) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5003446 | 0.85 | MAPT (0.47) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4996877 | 0.85 | NPC1 (0.45) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4995201 | 0.84 | MAPT (0.44) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4993024 | 0.83 | RIPK3 (0.44) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4996035 | 0.82 | SMN1; SMN2 (0.49) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5003303 | 0.81 | MAPT (0.48) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5003195 | 0.78 | PIM2 (0.50) | NPC1RAB9AMAPTSMN1; SMN2CHEK1 | |
| SCHEMBL5000611 | 0.78 | LMNA (0.45) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | NPC1 2008/4885RAB9A 2969/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.